Krokus PE’s country fund for Poland, Nova Polonia Natexis II, has acquired 44 per cent of the shares in Polmed via a capital increase to finance the further expansion of the company’s business.
Polmed provides healthcare to individuals, corporations and institutions. The range of services includes basic treatment, specialist ambulatory treatment, complete medical diagnostics, rehabilitation, dental treatment and minor surgical interventions.
Polmed runs a network of ten outpatient clinics mainly in northern Poland and cooperates with sub-contracting clinics in other parts of the country. Its medical personnel include doctors, specialists, nurses and midwives. Patients have at their disposal a 24 hour call centre and high quality medical equipment.
Krokus PE is the adviser to Nova Polonia Natexis II Private Equity Fund, which invests in expansion and buy-out opportunities in Poland. The total value of the fund amounts to EUR100m.
Among companies the fund has already invested in are: Comfort, a supplier of large prefabricated concrete elements; Odratrans, one of the largest inland shipping companies in Europe; Transsystem, a designer and manufacturer of industrial transportation systems; and Izoterm, a provider of thermal insulation services.
“The healthcare sector in Poland is large and growing, while increasing health awareness among Poles is inducing changes on this market. Polmed aims to fulfill patients’ expectations and has the potential to achieve it. The company’s skilled personnel and the competent management of its owners inclined us to make this investment. We believe that Polmed’s strategic objective of creating a nationwide chain of medical centres with a comprehensive scope of services will be accomplished efficiently in the midterm perspective,” says Witold Radwański, president and managing partner of Krokus PE.
“We want to create a nationwide health services company. We also perceive several market niches which we plan to fill. Demand for high standard medical services is still growing in Poland and our task is to satisfy it. Support from our financial investor will certainly speed up Polmed’s development and consequently strengthen its market position,” adds Radosław Szubert, chief executive and founder of Polmed.
